Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.

D P de Bono, M L Simoons, J Tijssen, A E Arnold, A Betriu, C Burgersdijk, L López Bescos, E Mueller, M Pfisterer, F Van de Werf

Glenfield General Hospital, Leicester.

OBJECTIVE--To determine whether concomitant treatment with intravenous heparin affects coronary patency and outcome in patients treated with alteplase thrombolysis for acute myocardial infarction. DESIGN--Double blind randomised trial. TREATMENT REGIMENS--Alteplase 100 mg (not weight adjusted) plus aspirin (250 mg intravenously followed by 75-125 mg on alternate days) plus heparin (5000 units intravenously followed by 1000 units hourly without dose adjustment) was compared with alteplase plus aspirin plus placebo for heparin. SETTING--19 cardiac centres in six European countries. SUBJECTS--652 patients aged 21-70 years with clinical and electrocardiographic features of infarcting myocardium in whom thrombolytic therapy could be started within six hours of the onset of major symptoms. MAIN OUTCOME MEASURE--Angiographic coronary patency 48-120 hours after randomisation. RESULTS--Coronary patency (TIMI grades 2 or 3) was 83.4% in the heparin group and 74.7% in the group given placebo for heparin. The relative risk of an occluded vessel in the heparin treated group was 0.66 (95% confidence interval 0.47 to 0.93). Mortality was the same in both groups. There were non-significant trends towards a smaller enzymatic infarct size and a higher incidence of bleeding complications in the group treated with heparin. CONCLUSIONS--Concomitant intravenous heparin improves coronary patency in patients with alteplase. Whether this can be translated into improved clinical benefit needs to be to be tested in a larger trial.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Effect of early intravenous heparin on coronary patency infarct size, and bleeding complications after alteplase thrombolysis

David R Massel and David De Bono
Heart 1992 68: 342. [PDF]

This article has been cited by other articles:

• Authors/Task Force Members, , Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Crea, F., Falk, V., Filippatos, G., Fox, K., Huber, K., Kastrati, A., Rosengren, A., Steg, P. G., Tubaro, M., Verheugt, F., Weidinger, F., Weis, M., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Silber, S., Aguirre, F. V., Al-Attar, N., Alegria, E., Andreotti, F., Benzer, W., Breithardt, O., Danchin, N., Mario, C. D., Dudek, D., Gulba, D., Halvorsen, S., Kaufmann, P., Kornowski, R., Lip, G. Y. H., Rutten, F. (2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. Eur Heart J 29: 2909-2945 [Full Text]  
• Goodman, S. G., Menon, V., Cannon, C. P., Steg, G., Ohman, E. M., Harrington, R. A. (2008). Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 708S-775S [Abstract] [Full Text]  
• Peters, R. J.G., Joyner, C., Bassand, J.-P., Afzal, R., Chrolavicius, S., Mehta, S. R., Oldgren, J., Wallentin, L., Budaj, A., Fox, K. A., Yusuf, S., for the OASIS-6 investigators, (2008). The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 29: 324-331 [Abstract] [Full Text]  
• Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., Lopez-Sendon, J. L., Guneri, S., Jiang, F., White, H. D., Fox, K. A.A., Braunwald, E., the ExTRACT-TIMI 25 Investigators, (2006). Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. NEJM 354: 1477-1488 [Abstract] [Full Text]  
• Eikelboom, J. W., Quinlan, D. J., Mehta, S. R., Turpie, A. G., Menown, I. B., Yusuf, S. (2005). Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials. Circulation 112: 3855-3867 [Abstract] [Full Text]  
• The CREATE Trial Group Investigators*, (2005). Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation. JAMA 293: 427-435 [Abstract] [Full Text]  
• Menon, V., Harrington, R. A., Hochman, J. S., Cannon, C. P., Goodman, S. D., Wilcox, R. G., Schunemann, H. J., Ohman, E. M. (2004). Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 549S-575S [Abstract] [Full Text]  
• Wallentin, L., Bergstrand, L., Dellborg, M., Fellenius, C., Granger, C. B, Lindahl, B., Lins, L.-E., Nilsson, T., Pehrsson, K., Siegbahn, A., Swahn, E., for the ASSENT PLUS Investigators, (2003). Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction--the ASSENT Plus study. Eur Heart J 24: 897-908 [Abstract] [Full Text]  
• The Task Force on the Management of Acute Myocardi, , Van de Werf, F., Ardissino, D., Betriu, A., Cokkinos, D. V., Falk, E., Fox, K. A.A., Julian, D., Lengyel, M., Neumann, F.-J., Ruzyllo, W., Thygesen, C., Underwood, S. R., Vahanian, A., Verheugt, F. W.A., Wijns, W. (2003). Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 24: 28-66 [Full Text]  
• Brouwer, M. A., van den Bergh, P. J.P.C., Aengevaeren, W. R.M., Veen, G., Luijten, H. E., Hertzberger, D. P., van Boven, A. J., Vromans, R. P.J.W., Uijen, G. J.H., Verheugt, F. W.A. (2002). Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 106: 659-665 [Abstract] [Full Text]  
• Simoons, M.L., Krzeminska-Pakula, M., Alonso, A., Goodman, S.G., Kali, A., Loos, U., Gosset, F., Louer, V., Bigonzi, F. (2002). Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 23: 1282-1290 [Abstract]  
• Zijlstra, F., Ernst, N., de Boer, M.-J., Nibbering, E., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J.-H. E., van't Hof, A. W. J., Verheugt, F. W. A. (2002). Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute st elevation myocardial infarction. J Am Coll Cardiol 39: 1733-1737 [Abstract] [Full Text]  
• Coussement, P.K, Bassand, J.-P, Convens, C, Vrolix, M, Boland, J, Grollier, G, Michels, R, Vahanian, A, Vanderheyden, M, Rupprecht, H.-J, Van de Werf, F (2001). A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 22: 1716-1724 [Abstract]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Arterioscler. Thromb. Vasc. Bio. 21 : e9-e9 [Full Text]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Circulation 103: 2994-3018 [Full Text]  
• Lopez-Sendon, J. (2001). Coronary reperfusion in the clinical setting: antithrombotic support to thrombolysis in the coronary care unit. Eur Heart J Suppl 3: C55-C61 [Abstract]  
• Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., Dalen, J. E. (2001). Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest 119 : 64S-94S [Full Text]  
• Ohman, E. M., Harrington, R. A., Cannon, C. P., Agnelli, G., Cairns, J. A., Kennedy, J.W. (2001). Intravenous Thrombolysis in Acute Myocardial Infarction. Chest 119 : 253S-277S [Full Text]  
• Nenci, G. G, Minciotti, A. (2000). Low molecular weight heparins for arterial thrombosis. Vasc Med 5: 251-258 [Abstract]  
• Liem, A., Zijlstra, F., Ottervanger, J. P., Hoorntje, J. C. A., Suryapranata, H., de Boer, M.-J., Verheugt, F. W. A. (2000). High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 35: 600-604 [Abstract] [Full Text]  
• Cannon, C. P. (1999). Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 34: 1395-1402 [Abstract] [Full Text]  
• Frostfeldt, G., Ahlberg, G., Gustafsson, G., Helmius, G., Lindahl, B., Nygren, A., Siegbahn, A., Swahn, E., Venge, P., Wallentin, L. (1999). Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction--a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 33: 627-633 [Abstract] [Full Text]  
• Chamuleau, S A J, de Winter, R J, Levi, M, Adams, R, Büller, H R, Prins, M H, Lie, K I, Peters, R J G (1998). Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Heart 80: 35-39 [Abstract] [Full Text]  
• White, R. L (1998). Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update. Asian Cardiovasc. Thorac. Ann. 6: 03-10 [Abstract] [Full Text]  
• Collins, R., Peto, R., Baigent, C., Sleight, P. (1997). Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. NEJM 336: 847-860 [Full Text]  
• McKenzie, C. R., Abendschein, D. R., Eisenberg, P. R. (1996). Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa. Arterioscler. Thromb. Vasc. Bio. 16: 1285-1291 [Abstract] [Full Text]  
• Collins, R., MacMahon, S., Flather, M., Baigent, C., Remvig, L., Mortensen, S., Appleby, P., Godwin, J., Yusuf, S., Peto, R. (1996). Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 313: 652-659 [Abstract] [Full Text]  
• Simes, R.J., Topol, E. J., Holmes, D. R. Jr, White, H. D., Rutsch, W. R., Vahanian, A., Simoons, M. L., Morris, D., Betriu, A., Califf, R. M., Ross, A. M. (1995). Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion : Importance of Early and Complete Infarct Artery Reperfusion. Circulation 91: 1923-1928 [Abstract] [Full Text]  
• Gunnarsson, P. S., Sawyer, W. T., Montague, D., Williams, M. L., Dupuis, R. E., Caiola, S. M. (1995). Appropriate Use of Heparin: Empiric vs Nomogram-Based Dosing. Arch Intern Med 155: 526-532 [Abstract]  
• Leya, F., Fareed, J., Walenga, J. (1995). Acute Myocardial Infarction: Diagnosis and Management. CLIN APPL THROMB HEMOST 1: 160-165 [Abstract]  
• Stassen, J. M., Nystrom, A., Hoylaerts, M., Collen, D. (1995). Antithrombotic Effects of Thrombolytic Agents in a Platelet-Rich Femoral Vein Thrombosis Model in the Hamster. Circulation 91: 1330-1335 [Abstract] [Full Text]  
• Flaker, G. C., Bartolozzi, J., Davis, V., McCabe, C., Cannon, C. P. (1994). Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation After Thrombolytic Therapy in Myocardial Infarction. Arch Intern Med 154: 1492-1496 [Abstract]  
• The GUSTO Angiographic Investigators, (1993). The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction. NEJM 329: 1615-1622 [Abstract] [Full Text]  
• The GUSTO Investigators, (1993). An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. NEJM 329: 673-682 [Abstract] [Full Text]  
• Anderson, H. V., Willerson, J. T. (1993). Thrombolysis in Acute Myocardial Infarction. NEJM 329: 703-709 [Full Text]  
• Fuster, V. (1993). Coronary Thrombolysis -- A Perspective for the Practicing Physician. NEJM 329: 723-725 [Full Text]  
• Zijlstra, F., de Boer, M. J., Hoorntje, J., Reiffers, S., Reiber, J., Suryapranata, H. (1993). A Comparison of Immediate Coronary Angioplasty with Intravenous Streptokinase in Acute Myocardial Infarction. NEJM 328: 680-684 [Abstract] [Full Text]  
• Antman, E. M., Louwerenburg, H. W., Baars, H. F., Wesdorp, J. C.L., Hamer, B., Bassand, J.-P., Bigonzi, F., Pisapia, G., Gibson, C. M., Heidbuchel, H., Braunwald, E., Van de Werf, F., for the ENTIRE-TIMI 23 Investigators, (2002). Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105: 1642-1649 [Abstract] [Full Text]